Folgen
Boris Hadaschik
Boris Hadaschik
University Hospital Essen, Dept. of Urology
Bestätigte E-Mail-Adresse bei uk-essen.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
MRI-targeted or standard biopsy for prostate-cancer diagnosis
V Kasivisvanathan, AS Rannikko, M Borghi, V Panebianco, LA Mynderse, ...
New England Journal of Medicine 378 (19), 1767-1777, 2018
18822018
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
A Afshar-Oromieh, E Avtzi, FL Giesel, T Holland-Letz, HG Linhart, M Eder, ...
European journal of nuclear medicine and molecular imaging 42 (2), 197-209, 2015
9822015
Apalutamide treatment and metastasis-free survival in prostate cancer
MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ...
New England Journal of Medicine 378 (15), 1408-1418, 2018
9662018
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
A Afshar-Oromieh, CM Zechmann, A Malcher, M Eder, M Eisenhut, ...
European journal of nuclear medicine and molecular imaging 41 (1), 11-20, 2014
9342014
PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
A Afshar-Oromieh, A Malcher, M Eder, M Eisenhut, HG Linhart, ...
European journal of nuclear medicine and molecular imaging 40 (4), 486-495, 2013
8832013
Detection of clinically significant prostate cancer using magnetic resonance imaging–ultrasound fusion targeted biopsy: a systematic review
M Valerio, I Donaldson, M Emberton, B Ehdaie, BA Hadaschik, LS Marks, ...
European urology 68 (1), 8-19, 2015
4672015
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group
CM Moore, V Kasivisvanathan, S Eggener, M Emberton, JJ Fütterer, ...
European urology 64 (4), 544-552, 2013
4102013
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
FL Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, ...
European journal of nuclear medicine and molecular imaging 44 (4), 678-688, 2017
4082017
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
CM Zechmann, A Afshar-Oromieh, T Armor, JB Stubbs, W Mier, ...
European journal of nuclear medicine and molecular imaging 41 (7), 1280-1292, 2014
3602014
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience
A Afshar-Oromieh, U Haberkorn, HP Schlemmer, M Fenchel, M Eder, ...
European journal of nuclear medicine and molecular imaging 41 (5), 887-897, 2014
3402014
Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT
M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ...
Journal of Nuclear Medicine 59 (3), 469-478, 2018
2822018
Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen
JP Radtke, C Schwab, MB Wolf, MT Freitag, CD Alt, C Kesch, ...
European urology 70 (5), 846-853, 2016
2472016
A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion
BA Hadaschik, TH Kuru, C Tulea, P Rieker, IV Popeneciu, ...
The Journal of urology 186 (6), 2214-2220, 2011
2052011
Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion …
JP Radtke, TH Kuru, S Boxler, CD Alt, IV Popeneciu, C Huettenbrink, ...
The Journal of urology 193 (1), 87-94, 2015
2022015
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer
TH Kuru, MC Roethke, J Seidenader, T Simpfendörfer, S Boxler, ...
The Journal of urology 190 (4), 1380-1386, 2013
2022013
The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction
FA Distler, JP Radtke, D Bonekamp, C Kesch, HP Schlemmer, ...
The Journal of urology 198 (3), 575-582, 2017
1722017
Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla
MC Roethke, TH Kuru, S Schultze, D Tichy, A Kopp-Schneider, M Fenchel, ...
European radiology 24 (2), 344-352, 2014
1592014
Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer
MT Freitag, JP Radtke, BA Hadaschik, A Kopp-Schneider, M Eder, ...
European journal of nuclear medicine and molecular imaging 43 (1), 70-83, 2016
1532016
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
RD Sowery, BA Hadaschik, AI So, A Zoubeidi, L Fazli, A Hurtado‐Coll, ...
BJU international 102 (3), 389-397, 2008
1422008
Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values
D Bonekamp, S Kohl, M Wiesenfarth, P Schelb, JP Radtke, M Götz, ...
Radiology 289 (1), 128-137, 2018
1412018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20